Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
CVR Energy Prices 10,515,248-Share Offering at $47.55 a Share

CVR Energy Prices 10,515,248-Share Offering at $47.55 a Share

BitgetBitget2026/11/04 03:15
  • CVR Energy priced an underwritten public offering of 10,515,248 common shares at $47.55 per share.
  • Underwriters have a 30-day option to purchase up to 1,577,287 additional shares, equal to 15% of the offering.
  • Expected net proceeds total approximately $490 million; closing is scheduled for November 5, 2026, subject to customary conditions.
  • Proceeds will help fund the acquisition of the St. Paul Park and Mandan refineries and related marketing business.
  • Funds will also redeem outstanding 5.750% Senior Notes due 2028 and cover related fees and expenses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVR Energy Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611032215BIZWIRE_USPR_____20261103_BW504060) on November 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss